Twist Bioscience Corp. (TWST)
139.92
+4.45
(+3.28%)
USD |
NASDAQ |
Oct 23, 16:00
138.96
-0.96
(-0.69%)
After-Hours: 20:00
Twist Bioscience Enterprise Value : 8.696B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 8.696B |
| October 22, 2026 | 8.417B |
| October 21, 2026 | 9.273B |
| October 20, 2026 | 8.870B |
| October 19, 2026 | 8.687B |
| October 16, 2026 | 8.247B |
| October 15, 2026 | 8.983B |
| October 14, 2026 | 9.213B |
| October 13, 2026 | 9.411B |
| October 12, 2026 | 9.444B |
| October 09, 2026 | 9.941B |
| October 08, 2026 | 9.456B |
| October 07, 2026 | 9.682B |
| October 06, 2026 | 10.39B |
| October 05, 2026 | 12.77B |
| October 02, 2026 | 11.75B |
| October 01, 2026 | 11.71B |
| September 30, 2026 | 12.04B |
| September 29, 2026 | 11.59B |
| September 28, 2026 | 11.18B |
| September 25, 2026 | 11.39B |
| September 24, 2026 | 11.46B |
| September 23, 2026 | 9.861B |
| September 22, 2026 | 10.24B |
| September 21, 2026 | 10.32B |
| Date | Value |
|---|---|
| September 18, 2026 | 10.39B |
| September 17, 2026 | 9.676B |
| September 16, 2026 | 8.894B |
| September 15, 2026 | 8.582B |
| September 14, 2026 | 8.372B |
| September 11, 2026 | 7.900B |
| September 10, 2026 | 7.877B |
| September 09, 2026 | 7.794B |
| September 08, 2026 | 7.953B |
| September 04, 2026 | 7.743B |
| September 03, 2026 | 7.994B |
| September 02, 2026 | 8.137B |
| September 01, 2026 | 8.203B |
| August 31, 2026 | 8.638B |
| August 28, 2026 | 8.788B |
| August 27, 2026 | 9.522B |
| August 26, 2026 | 9.332B |
| August 25, 2026 | 9.417B |
| August 24, 2026 | 8.751B |
| August 21, 2026 | 9.051B |
| August 20, 2026 | 8.471B |
| August 19, 2026 | 8.851B |
| August 18, 2026 | 7.203B |
| August 17, 2026 | 7.724B |
| August 14, 2026 | 7.358B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.205B |
| Beam Therapeutics, Inc. | 1.578B |
| 10X Genomics, Inc. | 8.848B |
| Prime Medicine, Inc. | 680.71M |
| Moderna, Inc. | 75.99B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.05M |
| Revenue (Quarterly) | 118.38M |
| Total Expenses (Quarterly) | 153.43M |
| EPS Diluted (Quarterly) | -0.5617 |
| Gross Profit Margin (Quarterly) | 52.76% |
| Profit Margin (Quarterly) | -29.61% |
| Earnings Yield | -1.59% |
| Normalized Earnings Yield | -1.531 |